Louisa Degenhardt1, Sukanta Saha2, Carmen C W Lim2, Sergio Aguilar-Gaxiola3, Ali Al-Hamzawi4, Jordi Alonso5,6,7, Laura H Andrade8, Evelyn J Bromet9, Ronny Bruffaerts10, José Miguel Caldas-de-Almeida11, Giovanni de Girolamo12, Silvia Florescu13, Oye Gureje14, Josep M Haro15, Elie G Karam16,17,18, Georges Karam16,17,18, Viviane Kovess-Masfety19,20, Sing Lee21, Jean-Pierre Lepine22, Victor Makanjuola14, Maria E Medina-Mora23, Zeina Mneimneh24, Fernando Navarro-Mateu25, Marina Piazza26,27, José Posada-Villa28, Nancy A Sampson29, Kate M Scott30, Juan Carlos Stagnaro31, Margreet Ten Have32, Kenneth S Kendler33, Ronald C Kessler29, John J McGrath34,35. 1. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW. 2. Queensland Centre for Mental Health Research, and Queensland Brain Institute, The University of Queensland, St Lucia, Queensland, Australia. 3. Center for Reducing Health Disparities, UC Davis Health System, Sacramento, CA, USA. 4. College of Medicine, Al-Qadisiya University, Diwaniya governorate, Iraq. 5. Health Services Research Unit, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain. 6. Pompeu Fabra University (UPF), Barcelona, Spain. 7. CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. 8. Núcleo de Epidemiologia Psiquiátrica-LIM 23, Instituto de Psiquiatria Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Brazil. 9. Department of Psychiatry, Stony Brook University School of Medicine, Stony Brook, NY, USA. 10. Universitair Psychiatrisch Centrum, Katholieke Universiteit Leuven (UPC-KUL), Campus Gasthuisberg, Leuven, Belgium. 11. Lisbon Institute of Global Mental Health and Chronic Diseases Research Center (CEDOC), NOVA Medical School | Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal. 12. Unit of Epidemiological and Evaluation Psychiatry, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS)-St John of God Clinical Research Centre, Brescia, Italy. 13. National School of Public Health, Management and Professional Development, Bucharest, Romania. 14. Department of Psychiatry, University College Hospital, Ibadan, Nigeria. 15. Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain. 16. Department of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University, Beirut, Lebanon. 17. Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center, Beirut, Lebanon. 18. Institute for Development Research Advocacy and Applied Care (IDRAAC), Beirut, Lebanon. 19. EHESP Dpt MéTis Epidémiologie et biostatistiques pour la décision en santé publique /Laboratoire Psychopathologie et Processus de Santé (EA 4057), Université Paris Descartes EHESP School for Public Health, Paris, France. 20. Department of Health Epidemiology and biostatistics for decision making in public health /EA 4057, Paris Descartes University, Paris, France. 21. Department of Psychiatry, Chinese University of Hong Kong, Tai Po, Hong Kong. 22. Hôpital Lariboisière-Fernand Widal, Assistance Publique Hôpitaux de Paris, Universités Paris Descartes-Paris Diderot, Paris, France. 23. National Institute of Psychiatry Ramón de la Fuente, Mexico City, México. 24. Survey Research Center, University of Michigan, Ann Arbor, MI, USA. 25. UDIF-SM, Subdirección General de Planificación, Innovación y Cronicidad, Servicio Murciano de Salud. IMIB-Arrixaca, CIBERESP-Murcia, Murcia, Spain. 26. Universidad Cayetano Heredia, Lima, Peru. 27. National Institute of Health, Lima, Peru. 28. Faculty of Social Sciences, Colegio Mayor de Cundinamarca University, Bogota, Colombia. 29. Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. 30. Department of Psychological Medicine, University of Otago, Dunedin, Otago, New Zealand. 31. Departamento de Psiquiatría y Salud Mental, Facultad de Medicina, Universidad de Buenos Aires, Argentina. 32. Trimbos-Instituut, Netherlands Institute of Mental Health and Addiction, Utrecht, the Netherlands. 33. Department of Psychiatry, Virginia Commonwealth University, Virginia, USA. 34. Queensland Centre for Mental Health Research, and Queensland Brain Institute, University of Queensland, St Lucia, Queensland, Australia. 35. National Centre for Register-based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark.
Abstract
BACKGROUND AND AIMS: Prior research has found bidirectional associations between psychotic experiences (PEs) and selected substance use disorders. We aimed to extend this research by examining the bidirectional association between PEs and various types of substance use (SU) and substance use disorders (SUDs), and the influence of antecedent mental disorders on these associations. DESIGN, SETTING, PARTICIPANTS AND MEASUREMENTS: We used data from the World Health Organization World Mental Health surveys. A total of 30 902 adult respondents across 18 countries were assessed for (a) six types of life-time PEs, (b) a range of types of SU and DSM-IV SUDs and (c) mental disorders using the Composite International Diagnostic Interview. Discrete-time survival analyses based on retrospective age-at-onset reports examined the bidirectional associations between PEs and SU/SUDs controlling for antecedent mental disorders. FINDINGS: After adjusting for demographics, comorbid SU/SUDs and antecedent mental disorders, those with prior alcohol use disorders [odds ratio (OR) = 1.6, 95% confidence interval (CI) = 1.2-2.0], extra-medical prescription drug use (OR = 1.5, 95% CI = 1.1-1.9), alcohol use (OR = 1.4, 95% CI = 1.1-1.7) and tobacco use (OR = 1.3, 95% CI = 1.0-1.8) had increased odds of subsequent first onset of PEs. In contrast, those with temporally prior PEs had increased odds of subsequent onset of tobacco use (OR = 1.5, 95% CI = 1.2-1.9), alcohol use (OR = 1.3, 95% CI = 1.1-1.6) or cannabis use (OR = 1.3, 95% CI = 1.0-1.5) as well as of all substance use disorders (ORs ranged between 1.4 and 1.5). There was a dose response relationship between both count and frequency of PEs and increased subsequent odds of selected SU/SUDs. CONCLUSIONS: Associations between psychotic experiences (PEs) and substance use/substance use disorders (SU/SUDs) are often bidirectional, but not all types of SU/SUDs are associated with PEs. These findings suggest that it is important to be aware of the presence of PEs within those with SUDs or at risk of SUDs, given the plausibility that they may each impact upon the other.
BACKGROUND AND AIMS: Prior research has found bidirectional associations between psychotic experiences (PEs) and selected substance use disorders. We aimed to extend this research by examining the bidirectional association between PEs and various types of substance use (SU) and substance use disorders (SUDs), and the influence of antecedent mental disorders on these associations. DESIGN, SETTING, PARTICIPANTS AND MEASUREMENTS: We used data from the World Health Organization World Mental Health surveys. A total of 30 902 adult respondents across 18 countries were assessed for (a) six types of life-time PEs, (b) a range of types of SU and DSM-IV SUDs and (c) mental disorders using the Composite International Diagnostic Interview. Discrete-time survival analyses based on retrospective age-at-onset reports examined the bidirectional associations between PEs and SU/SUDs controlling for antecedent mental disorders. FINDINGS: After adjusting for demographics, comorbid SU/SUDs and antecedent mental disorders, those with prior alcohol use disorders [odds ratio (OR) = 1.6, 95% confidence interval (CI) = 1.2-2.0], extra-medical prescription drug use (OR = 1.5, 95% CI = 1.1-1.9), alcohol use (OR = 1.4, 95% CI = 1.1-1.7) and tobacco use (OR = 1.3, 95% CI = 1.0-1.8) had increased odds of subsequent first onset of PEs. In contrast, those with temporally prior PEs had increased odds of subsequent onset of tobacco use (OR = 1.5, 95% CI = 1.2-1.9), alcohol use (OR = 1.3, 95% CI = 1.1-1.6) or cannabis use (OR = 1.3, 95% CI = 1.0-1.5) as well as of all substance use disorders (ORs ranged between 1.4 and 1.5). There was a dose response relationship between both count and frequency of PEs and increased subsequent odds of selected SU/SUDs. CONCLUSIONS: Associations between psychotic experiences (PEs) and substance use/substance use disorders (SU/SUDs) are often bidirectional, but not all types of SU/SUDs are associated with PEs. These findings suggest that it is important to be aware of the presence of PEs within those with SUDs or at risk of SUDs, given the plausibility that they may each impact upon the other.
Authors: Joel Swendsen; Kevin P Conway; Louisa Degenhardt; Meyer Glantz; Robert Jin; Kathleen R Merikangas; Nancy Sampson; Ronald C Kessler Journal: Addiction Date: 2010-03-10 Impact factor: 6.526
Authors: John McGrath; Joy Welham; James Scott; Daniel Varghese; Louisa Degenhardt; Mohammad Reza Hayatbakhsh; Rosa Alati; Gail M Williams; William Bor; Jake M Najman Journal: Arch Gen Psychiatry Date: 2010-03-01
Authors: Meyer D Glantz; Maria Elena Medina-Mora; Maria Petukhova; Laura Helena Andrade; James C Anthony; Giovanni de Girolamo; Ron de Graaf; Louisa Degenhardt; Koen Demyttenaere; Silvia Florescu; Oye Gureje; Josep Maria Haro; Itsuko Horiguchi; Elie G Karam; Stanislav Kostyuchenko; Sing Lee; Jean-Pierre Lépine; Herbert Matschinger; Yehuda Neumark; Jose Posada-Villa; Rajesh Sagar; Dan J Stein; Toma Tomov; J Elisabeth Wells; Somnath Chatterji; Ronald C Kessler Journal: Am J Addict Date: 2013-08-29
Authors: Alessio Fiorentini; Lucia Sara Volonteri; Filippo Dragogna; Chiara Rovera; Michele Maffini; Massimo Carlo Mauri; Carlo A Altamura Journal: Curr Drug Abuse Rev Date: 2011-12
Authors: Oliver D Howes; Colm McDonald; Mary Cannon; Louise Arseneault; Jane Boydell; Robin M Murray Journal: Int J Neuropsychopharmacol Date: 2004-03 Impact factor: 5.176
Authors: Matthew J Smith; Jagadisha Thirthalli; Arbi Ben Abdallah; Robin M Murray; Linda B Cottler Journal: Compr Psychiatry Date: 2008-09-23 Impact factor: 3.735
Authors: Stanley Zammit; Theresa H M Moore; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis Journal: Br J Psychiatry Date: 2008-11 Impact factor: 9.319
Authors: Amanda R Bolbecker; Deborah Apthorp; Ashley Schnakenberg Martin; Behdad Tahayori; Leah Moravec; Karen L Gomez; Brian F O'Donnell; Sharlene D Newman; William P Hetrick Journal: Drug Alcohol Depend Date: 2018-06-21 Impact factor: 4.492
Authors: Katherine E Venturo-Conerly; Natalie E Johnson; Tom L Osborn; Eve S Puffer; Thomas Rusch; David M Ndetei; Christine M Wasanga; Victoria Mutiso; Christine Musyimi; John R Weisz Journal: Trials Date: 2022-05-25 Impact factor: 2.728
Authors: Massimo Clerici; Andrea de Bartolomeis; Sergio De Filippis; Giuseppe Ducci; Icro Maremmani; Giovanni Martinotti; Fabrizio Schifano Journal: Front Psychiatry Date: 2018-11-13 Impact factor: 4.157
Authors: Judit García-González; Julia Ramírez; David M Howard; Caroline H Brennan; Patricia B Munroe; Robert Keers Journal: Transl Psychiatry Date: 2020-09-28 Impact factor: 6.222
Authors: Jessica Neicun; Justin Christopher Yang; Hueyjong Shih; Pranay Nadella; Robin van Kessel; Attilio Negri; Kasia Czabanowska; Carol Brayne; Andres Roman-Urrestarazu Journal: PLoS One Date: 2020-10-30 Impact factor: 3.240